Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 2Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1Bone Marrow Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × darinaparsin × Clear all
NCT02653976 2024-01-26

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Solasia Pharma K.K.

Phase 2 Completed
67 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00423306 2013-11-14

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Alaunos Therapeutics

Phase 2 Unknown
15 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00423644 2013-11-14

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Alaunos Therapeutics

Phase 2 Unknown
17 enrolled
Plasma cell

Multiple Myeloma

NCT00421213 2012-07-19

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Alaunos Therapeutics

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Bone Marrow Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡